Abstracts Archive - Page 41 of 2616 - ACR Meeting Abstracts

Abstract Number: 0533 • ACR Convergence 2025
Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Avarna Agarwal¹, Phanidhar Dhanekula¹, Sarthak Verma¹, Subham ravi Nayak², Prakashini Mruthyanjaya¹, Prasanta Padhan¹, A Rajkumar Patro², Ramnath Misra¹ and Sakir Ahmed¹, ¹Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India, ²Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India
Background/Purpose: In reactive arthritis (ReA) approximately a half of patients achieve drug-free remission (DFR), while others develop chronic disease. To identify predictive biomarkers for DFR,…
Abstract Number: 0398 • ACR Convergence 2025
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy² and Ginger Janow³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ³Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0515 • ACR Convergence 2025
Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Nikolaos Marketos¹, Charalampos Skarlis¹, Sylvia Raftopoulou¹, Ada Gjyrezi², Paul Zumbo³, Doron Betel³, Ioanna E. Stergiou⁴, Michael Voulgarelis⁴, Paraskevi Giannakakou⁵ and Clio Mavragani⁶, ¹Molecular Physiology and Clinical Applications Unit, Department of Physiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Department of Physiology , National & Kapodistrian University of Athens, Athens, Greece, New York, ³Department of Physiology & Biophysics, Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA, New York, ⁴Outpatient Rheumatology Clinic, Department of Pathophysiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA, New York, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Oral and ocular dryness are hallmarks in patients with Sjögren’s disease (SjD). Given that activation of interferon (IFN) pathways has been shown to be…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…
Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Solana Cushing¹, Susan Goodman², Michael Parides¹, Hadeel Abdul-Rehman¹, Daniel Ramirez², Edward DiCarlo², Kristine Carandang³, Renee Davis⁴, Rebecca Blank⁵, Laura Donlin¹, Anna Helena Jonsson⁶, Amit Lakhanpal², Bella Mehta⁷, Dana Orange⁸ and Melanie smith², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ⁴New York, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ⁸The Rockefeller University, New York, NY
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Ernest Choy¹, Marco Gattorno², Kamila Klama³, Andras Illes⁴, Peter Baker⁵, Maria Romanova Michailidi⁶ and Anna Zubrzycka-Sienkiewicz⁷, ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ²IRCCS G. Gaslini, Genova, Genoa, Italy, ³Solumed Clinical Research Center, Poznan, Poland, ⁴Fresenius Kabi SwissBioSim, Eysin, Switzerland, ⁵Fresenius Kabi Biopharma, Eysins, Switzerland, ⁶University of Geneva, Eysins, Switzerland, ⁷Reumatika - Centrum Reumatologii, Warszawa, Poland
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…
Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Pierre-Marie Duret¹, Maude Bouchard-Marmen², Loukas Chatzis³, Margherita Giannini⁴, François Severac⁵, FELTEN Renaud⁶, Dan Levy⁷, Benoit Nespola⁸, Emmanuel Chatelus⁹, Emmanuelle Dernis¹⁰, Valerie Devauchelle¹¹, Philippe Dieude¹², Jean-Jacques Dubost¹³, Anne-Laure Fauchais¹⁴, Bernard Geny¹⁵, Eric Hachulla¹⁶, Claire larroche¹⁷, Véronique Le Guern¹⁸, Jacques Morel¹⁹, Aleth Perdriger²⁰, Carine Salliot²¹, Alain SARAUX²², Damien Sène²³, Jean Sibilia²⁴, SORDET Christelle⁶, Olivier Vittecoq²⁵, Raphaele Seror²⁶, Gaetane Nocturne²⁷, Andreas Goules²⁸, Athanasios G. Tzioufas²⁹, Xavier Mariette³⁰, Jacques-eric GOTTENBERG³¹ and Alain Meyer³², ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²CHU de Québec, Québec, QC, Canada, ³Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁴Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁵Département de Santé Publique, Groupe Méthodes en Recherche Clinique (GMRC), CHU de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁶Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁷Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁸Laboratoire d’Immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁰Service de Rhumatologie, Centre Hospitalier Le Mans, Le Mans, Le Mans, France, ¹¹UBO, Brest, France, ¹²Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, Clermont-Ferrand, France, ¹⁴UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, France, ¹⁵UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ¹⁶Service de Médecine Interne et Immunologie Clinique, CHU de Lille, Hôpital Claude Huriez, Lille, Lille, France, ¹⁷Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹⁸Cochin hospital, Paris, France, ¹⁹CHU and University of Montpellier, Montpellier, France, ²⁰Rennes University, Rennes, France, ²¹CHR orleans, Orleans, France, ²²CHU Brest, Brest, France, ²³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ²⁴Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ²⁵Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ²⁶Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ²⁸Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, Greece, ²⁹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, ³⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ³¹Hautepierre Hospital, STRASBOURG, Alsace, France, ³²Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…
Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Hideto Kameda¹, Toshiya Takahashi², Naoki Soeda² and Yoshiya Tanaka³, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0548 • ACR Convergence 2025
Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
Seonyoung Kang¹, Yunseo Kim², Seulkee Lee³, Myung Jin Chung⁴, Hyungjin Kim⁵, Jaejoon Lee⁴, Hakje Yoo⁶ and Hoon-Suk Cha⁴, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ²Samsung Medical Center, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: The Assessment of SpondyloArthritis International Society (ASAS) criteria define positive MRI findings based on the presence of bone marrow edema (BME) in the sacroiliac…
Abstract Number: 0474 • ACR Convergence 2025
Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
Joseph Nathan¹, Bayram Farisogullari², Nicholas Jones³, Mohammad Ayoub³, James Brown³, Sarah Levy³, James Brader⁴, Ayse Ersoy⁴, Blossom Israni⁴, Mark Lloyd⁴, Afzal Latheef⁵, Diane Hill⁵, Amybel Taylor⁶, Darshani Arachchige⁶, Hlaing Chitsu⁶, Helen Linklater⁶, Kunal Lather⁷, Luke Gompels⁷, Eman Elfar⁸, Ritu Malaiya⁸, Pedro Machado⁹ and Patrick Kiely¹⁰, ¹St George's Hospital, London, United Kingdom, ²University College London, London, ³Croydon Health Services NHS Trust, Croydon, England, United Kingdom, ⁴Frimley Health NHS Foundation Trust, Frimley, England, United Kingdom, ⁵St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom, ⁶Surrey and Sussex Healthcare NHS Trust, Redhill, England, United Kingdom, ⁷Somerset NHS Foundation Trust, Taunton, England, United Kingdom, ⁸Epsom and St Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom, ⁹Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The use of Janus Kinase inhibitors (JAKi) to treat RA and PsA in a real-world setting has not been well described. Our aim was…
Abstract Number: 0748 • ACR Convergence 2025
Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
Iztok HOLC¹, Metka Koren Krajnc², Marko Gačnik³ and Anja Lah⁴, ¹University Medical Center Maribor, ²⁰⁰⁰ Maribor, Slovenia, ²University Medical center, Maribor, Slovenia, ³University Medical Center Maribor, Braslovče, Slovenia, ⁴University Medical Center Maribor, Laporje, Slovenia
Background/Purpose: Giant cell arteritis (GCA) is a chronic vasculitis where relapses frequently occur. The rates of relapses of GCA have not been defined by now.We…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].